Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Operating Leases: 2022-2024

Historic Operating Leases for Dianthus Therapeutics (DNTH) over the last 3 years, with Dec 2024 value amounting to $1.2 million.

  • Dianthus Therapeutics' Operating Leases was N/A to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year change of. This contributed to the annual value of $1.2 million for FY2024, which is 597.02% up from last year.
  • According to the latest figures from FY2024, Dianthus Therapeutics' Operating Leases is $1.2 million, which was up 597.02% from $168,000 recorded in FY2023.
  • Dianthus Therapeutics' Operating Leases' 5-year high stood at $1.2 million during FY2024, with a 5-year trough of $168,000 in FY2023.
  • For the 3-year period, Dianthus Therapeutics' Operating Leases averaged around $592,333, with its median value being $438,000 (2022).
  • As far as peak fluctuations go, Dianthus Therapeutics' Operating Leases crashed by 61.64% in 2023, and later skyrocketed by 597.02% in 2024.
  • Over the past 3 years, Dianthus Therapeutics' Operating Leases (Yearly) stood at $438,000 in 2022, then plummeted by 61.64% to $168,000 in 2023, then skyrocketed by 597.02% to $1.2 million in 2024.